Inhibition of the Hantavirus Fusion Process by Predicted Domain III and Stem Peptides from Glycoprotein Gc

PLoS Neglected Tropical Diseases

Volumn 10, Issue 7, 2016, Pages

  Barriga, Gonzalo P ^a,d   Villalón Letelier, Fernando ^a,e   Márquez, Chantal L ^a,f   Bignon, Eduardo A ^a   Acuña, Rodrigo ^a   Ross, Breyan H ^b,g   Monasterio, Octavio ^c   Mardones, Gonzalo A ^b   Vidal, Simon E ^a,h   Tischler, Nicole D ^a  

^a Fundacion Ciencia para la Vida   (Chile)

^b Universidad Austral de Chile   (Chile)

^c UNIVERSITY OF CHILE   (Chile)

^d Laboratorio de Neurociencia Cognitiva   (Chile)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

^g MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^h NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; GLUTATHIONE TRANSFERASE; GLYCOPROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN; PEPTIDE; PEPTIDES AND PROTEINS; POLYHISTIDINE; STEM PEPTIDE; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS FUSION PROTEIN;

ANDES VIRUS; ANIMAL CELL; ARTICLE; ASSAY; CELL FUSION; CONTROLLED STUDY; CYTOTOXICITY; HEMIFUSION ASSAY; HUMAN; HUMAN CELL; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; POLYMERIZATION; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN DOMAIN 3; PROTEIN EXPRESSION; PROTEIN PURIFICATION; PUUMALA VIRUS; SIMIAN IMMUNODEFICIENCY VIRUS; VESICULOVIRUS; VIRUS INACTIVATION; CHEMISTRY; GENETICS; HANTAVIRUS; HANTAVIRUS INFECTION; METABOLISM; PHYSIOLOGY; VIROLOGY; VIRUS ENTRY;

GLYCOPROTEINS; HANTAVIRUS; HANTAVIRUS INFECTIONS; HUMANS; PEPTIDES; PROTEIN DOMAINS; VIRAL ENVELOPE PROTEINS; VIRAL FUSION PROTEINS; VIRUS INTERNALIZATION;

EID: 84980348163     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0004799     Document Type: Article

References (80)

1. Figueiredo LT, Souza WM, Ferres M, Enria DA, Hantaviruses and cardiopulmonary syndrome in South America. Virus Res. 2014;187:43–54. doi: 10.1016/j.virusres.2014.01.01524508343
2. Kruger DH, Figueiredo LT, Song JW, Klempa B, Hantaviruses—globally emerging pathogens. J Clin Virol. 2015;64:128–36. doi: 10.1016/j.jcv.2014.08.03325453325
3. Macneil A, Nichol ST, Spiropoulou CF, Hantavirus pulmonary syndrome. Virus Res. 2011;162(1–2):138–47. doi: 10.1016/j.virusres.2011.09.01721945215
4. Jonsson CB, Figueiredo LT, Vapalahti O, A global perspective on hantavirus ecology, epidemiology, and disease. Clin Microbiol Rev. 2010;23(2):412–41. doi: 10.1128/CMR.00062-0920375360
5. Lee HW, Vaheri A, Schmaljohn CS, Discovery of hantaviruses and of the Hantavirus genus: personal and historical perspectives of the Presidents of the International Society of Hantaviruses. Virus Res. 2014;187:2–5. doi: 10.1016/j.virusres.2013.12.01924412711
6. Schmaljohn CS, Spik KW, Hooper JW, DNA vaccines for HFRS: laboratory and clinical studies. Virus Res. 2014;187:91–6. doi: 10.1016/j.virusres.2013.12.02024370868
7. Schmaljohn CS, Vaccines for hantaviruses: progress and issues. Expert Rev Vaccines. 2012;11(5):511–3. doi: 10.1586/erv.12.1522827236
8. Elliott RM, The Bunyaviridae. New York: Plenum Press; 1996.
9. Lyles DS, Assembly and budding of negative-strand RNA viruses. Adv Virus Res. 2013;85:57–90. doi: 10.1016/B978-0-12-408116-1.00003-323439024
10. Pettersson R, Melin L, Elliott RM, Synthesis, assembly and intracellular transport of Bunyaviridae membrane proteins. In: The Bunyaviridae. New York, NY: Plenum Press; 1996. pp. 88–159.
11. Gavrilovskaya IN, Shepley M, Shaw R, Ginsberg MH, Mackow ER, beta3 Integrins mediate the cellular entry of hantaviruses that cause respiratory failure. PNAS. 1998;95(12):7074–9. 9618541
12. Gavrilovskaya IN, Brown EJ, Ginsberg MH, Mackow ER, Cellular entry of hantaviruses which cause hemorrhagic fever with renal syndrome is mediated by beta3 integrins. J Virol. 1999;73(5):3951–9. 10196290
13. Choi Y, Kwon YC, Kim SI, Park JM, Lee KH, Ahn BY, A hantavirus causing hemorrhagic fever with renal syndrome requires gC1qR/p32 for efficient cell binding and infection. Virology. 2008;381(2):178–83. doi: 10.1016/j.virol.2008.08.03518834607
14. Krautkramer E, Zeier M, Hantavirus causing hemorrhagic fever with renal syndrome enters from the apical surface and requires decay-accelerating factor (DAF/CD55). J Virol. 2008;82(9):4257–64. doi: 10.1128/JVI.02210-0718305044
15. Jin M, Park J, Lee S, Park B, Shin J, Song KJ, et al. Hantaan virus enters cells by clathrin-dependent receptor-mediated endocytosis. Virology. 2002;294(1):60–9. 11886265
16. Ramanathan HN, Jonsson CB, New and Old World hantaviruses differentially utilize host cytoskeletal components during their life cycles. Virology. 2008;374(1):138–50. doi: 10.1016/j.virol.2007.12.03018234268
17. Acuña R, Bignon E, Mancini R, Lozach PY, Tischler ND, Acidification triggers Andes hantavirus membrane fusion and rearrangement of Gc into a stable post-fusion homotrimer. J Gen Virol. 2015. 96(11):3192–7. doi: 10.1099/jgv.0.00026926310672
18. Kielian M, Rey FA, Virus membrane-fusion proteins: more than one way to make a hairpin. Nat Rev Microbiol. 2006;4(1):67–76. 16357862
19. Harrison SC, Viral membrane fusion. Virology. 2015;479–480:498–507doi: 10.1016/j.virol.2015.03.04325866377
20. Modis Y, Relating structure to evolution in class II viral membrane fusion proteins. Curr Opin Virol. 2014;5:34–41. doi: 10.1016/j.coviro.2014.01.00924525225
21. Kielian M, Mechanisms of Virus Membrane Fusion Proteins. Annu Rev Virol. 2014;1:171–89. doi: 10.1146/annurev-virology-031413-08552126958720
22. Cifuentes-Muñoz N, Barriga GP, Valenzuela PDT, Tischler ND, Aromatic and polar residues spanning the candidate fusion peptide of Andes virus are essential for membrane fusion and Infection. J Gen Virol. 2011;92:552–63. doi: 10.1099/vir.0.027235-021123541
23. Tischler ND, Gonzalez A, Perez-Acle T, Rosemblatt M, Valenzuela PD, Hantavirus Gc glycoprotein: evidence for a class II fusion protein. J Gen Virol. 2005;86(Pt 11):2937–47. 16227214
24. Vaney MC, Rey FA, Class II enveloped viruses. Cell Microbiol. 2011;13(10):1451–9. doi: 10.1111/j.1462-5822.2011.01653.x21790946
25. Plassmeyer ML, Soldan SS, Stachelek KM, Roth SM, Martin-Garcia J, Gonzalez-Scarano F, Mutagenesis of the La Crosse Virus glycoprotein supports a role for Gc (1066–1087) as the fusion peptide. Virology. 2007;358(2):273–82. 17027056
26. Plassmeyer ML, Soldan SS, Stachelek KM, Martin-Garcia J, Gonzalez-Scarano F, California serogroup Gc (G1) glycoprotein is the principal determinant of pH-dependent cell fusion and entry. Virology. 2005;338(1):121–32. 15923017
27. Shi X, Goli J, Clark G, Brauburger K, Elliott RM, Functional analysis of the Bunyamwera orthobunyavirus Gc glycoprotein. J Gen Virol. 2009;90(Pt 10):2483–92. doi: 10.1099/vir.0.013540-019570952
28. Garry CE, Garry RF, Proteomics computational analyses suggest that the carboxyl terminal glycoproteins of Bunyaviruses are class II viral fusion protein (beta-penetrenes). Theor Biol Med Model. 2004;1:10. 15544707
29. Dessau M, Modis Y, Crystal structure of glycoprotein C from Rift Valley fever virus. Proc Natl Acad Sci U S A. 2013;110(5):1696–701. doi: 10.1073/pnas.121778011023319635
30. Kielian M, Class II virus membrane fusion proteins. Virology. 2006;344(1):38–47. 16364734
31. Rey FA, Heinz FX, Mandl C, Kunz C, Harrison SC, The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution. Nature. 1995;375(6529):291–8. 7753193
32. Allison SL, Stiasny K, Stadler K, Mandl CW, Heinz FX, Mapping of functional elements in the stem-anchor region of tick-borne encephalitis virus envelope protein E. J Virol. 1999;73(7):5605–12. 10364309
33. Zhang W, Chipman PR, Corver J, Johnson PR, Zhang Y, Mukhopadhyay S, et al. Visualization of membrane protein domains by cryo-electron microscopy of dengue virus. Nat Sruct Biol. 2003;10(11):907–12.
34. Zhang X, Ge P, Yu X, Brannan JM, Bi G, Zhang Q, et al. Cryo-EM structure of the mature dengue virus at 3.5-A resolution. Nature structural & molecular biology. 2013;20(1):105–10.
35. Gibbons DL, Vaney MC, Roussel A, Vigouroux A, Reilly B, Lepault J, et al. Conformational change and protein-protein interactions of the fusion protein of Semliki Forest virus. Nature. 2004;427(6972):320–5. 14737160
36. Bressanelli S, Stiasny K, Allison SL, Stura EA, Duquerroy S, Lescar J, et al. Structure of a flavivirus envelope glycoprotein in its low pH-induced membrane fusion conformation. EMBO J. 2004;23(4):728–38. 14963486
37. Klein DE, Choi JL, Harrison SC, Structure of a dengue virus envelope protein late-stage fusion intermediate. J Virol. 2013;87(4):2287–93. doi: 10.1128/JVI.02957-1223236058
38. DuBois RM, Vaney MC, Tortorici MA, Kurdi RA, Barba-Spaeth G, Krey T, et al. Functional and evolutionary insight from the crystal structure of rubella virus protein E1. Nature. 2013;493(7433):552–6. doi: 10.1038/nature1174123292515
39. Roman-Sosa G, Kielian M, The interaction of alphavirus E1 protein with exogenous domain III defines stages in virus-membrane fusion. J Virol. 2011;85(23):12271–9. doi: 10.1128/JVI.05902-1121937662
40. Pierson TC, Kielian M, Flaviviruses: braking the entering. Curr Opin Virol. 2013;3(1):3–12. doi: 10.1016/j.coviro.2012.12.00123352692
41. Eckert DM, Kim PS, Mechanisms of viral membrane fusion and its inhibition. Ann Rev Biochem. 2001;70:777–810. 11395423
42. Didigu CA, Doms RW, Novel approaches to inhibit HIV entry. Viruses. 2012;4(2):309–24. doi: 10.3390/v402030922470838
43. Matthews T, Salgo M, Greenberg M, Chung J, DeMasi R, Bolognesi D, Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nat Rev Drug Discov. 2004;3(3):215–25. 15031735
44. Liao M, Kielian M, Domain III from class II fusion proteins functions as a dominant-negative inhibitor of virus membrane fusion. J Cell Biol. 2005;171(1):111–20. 16216925
45. Hrobowski YM, Garry RF, Michael SF, Peptide inhibitors of dengue virus and West Nile virus infectivity. Virol J. 2005;2:49. 15927084
46. Koehler JW, Smith JM, Ripoll DR, Spik KW, Taylor SL, Badger CV, et al. A fusion-inhibiting peptide against Rift Valley fever virus inhibits multiple, diverse viruses. PLoS Negl Trop Dis. 2013;7(9):e2430. doi: 10.1371/journal.pntd.000243024069485
47. Schmidt AG, Yang PL, Harrison SC, Peptide inhibitors of dengue-virus entry target a late-stage fusion intermediate. PLoS pathogens. 2010;6(4):e1000851. doi: 10.1371/journal.ppat.100085120386713
48. Schmidt AG, Yang PL, Harrison SC, Peptide inhibitors of flavivirus entry derived from the E protein stem. J Virol. 2010;84(24):12549–54. doi: 10.1128/JVI.01440-1020881042
49. Tischler ND, Fernandez J, Muller I, Martinez R, Galeno H, Villagra E, et al. Complete sequence of the genome of the human isolate of Andes virus CHI-7913: comparative sequence and protein structure analysis. Biol Res. 2003;36(2):201–10. 14513715
50. Brocato RL, Josleyn MJ, Wahl-Jensen V, Schmaljohn CS, Hooper JW, Construction and nonclinical testing of a Puumala virus synthetic M gene-based DNA vaccine. Clin Vaccine Immunol. 2013;20(2):218–26. doi: 10.1128/CVI.00546-1223239797
51. Sheffield P, Garrard S, Derewenda Z, Overcoming expression and purification problems of RhoGDI using a family of "parallel" expression vectors. Protein Expr Purif. 1999;15(1):34–9. 10024467
52. Bhardwaj S, Holbrook M, Shope RE, Barrett AD, Watowich SJ, Biophysical characterization and vector-specific antagonist activity of domain III of the tick-borne flavivirus envelope protein. J Virol. 2001;75(8):4002–7. 11264392
53. Ross BH, Lin Y, Corales EA, Burgos PV, Mardones GA, Structural and functional characterization of cargo-binding sites on the mu4-subunit of adaptor protein complex 4. PLoS One2014; 9: e88147. doi: 10.1371/journal.pone.008814724498434
54. Compton LA, Johnson WC, JrAnalysis of protein circular dichroism spectra for secondary structure using a simple matrix multiplication. Analytical biochemistry. 1986;155(1):155–67. 3717552
55. van Stokkum IH, Spoelder HJ, Bloemendal M, van Grondelle R, Groen FC, Estimation of protein secondary structure and error analysis from circular dichroism spectra. Anal Biochem. 1990;191(1):110–8. 2077933
56. Provencher SW, Glockner J, Estimation of globular protein secondary structure from circular dichroism. Biochemistry. 1981;20(1):33–7. 7470476
57. Barriga GP, Martinez-Valdebenito C, Galeno H, Ferres M, Lozach PY, Tischler ND, A rapid method for infectivity titration of Andes hantavirus using flow cytometry. J Virol Methods. 2013;193(2):291–4. doi: 10.1016/j.jviromet.2013.06.02223806566
58. Tischler ND, Rosemblatt M, Valenzuela PD, Characterization of cross-reactive and serotype-specific epitopes on the nucleocapsid proteins of hantaviruses. Virus Res. 2008;135(1):1–9. doi: 10.1016/j.virusres.2008.01.01318342973
59. Cifuentes-Muñoz N, Darlix JL, Tischler ND, Development of a lentiviral vector system to study the Andes virus glycoproteins. Virus Res. 2010;153(1):29–35. doi: 10.1016/j.virusres.2010.07.00120619306
60. Mangeot PE, Duperrier K, Negre D, Boson B, Rigal D, Cosset FL, et al. High levels of transduction of human dendritic cells with optimized SIV vectors. Mol Ther. 2002;5(3):283–90. 11863418
61. Godoy P, Marsac D, Stefas E, Ferrer P, Tischler ND, Pino K, et al. Andes virus antigens are shed in urine of patients with acute hantavirus cardiopulmonary syndrome. J Virol. 2009;83(10):5046–55. doi: 10.1128/JVI.02409-0819279096
62. Acuña R, Cifuentes-Muñoz N, Márquez CL, Bulling M, Klingstrom J, Mancini R, et al. Hantavirus Gn and Gc glycoproteins self-assemble into virus-like particles. J Virol. 2014;88(4):2344–8. doi: 10.1128/JVI.03118-1324335294
63. Giraudo CG, Hu C, You D, Slovic AM, Mosharov EV, Sulzer D, et al. SNAREs can promote complete fusion and hemifusion as alternative outcomes. J Cell Biol. 2005;170(2):249–60. 16027221
64. Hofmann K, Stoffel W, TMbase—A database of membrane spanning proteins segments. Biol Chem Hoppe-Seyler. 1993;374:166.
65. Crooks GE, Hon G, Chandonia JM, Brenner SE, WebLogo: a sequence logo generator. Genome Res. 2004;14(6):1188–90. 15173120
66. Holmes EC, Zhang YZ, The evolution and emergence of hantaviruses. Curr Opin Virol. 2015; 10:27–33. doi: 10.1016/j.coviro.2014.12.00725562117
67. Volk DE, Beasley DW, Kallick DA, Holbrook MR, Barrett AD, Gorenstein DG, Solution structure and antibody binding studies of the envelope protein domain III from the New York strain of West Nile virus. J Biol Chem. 2004;279(37):38755–61. 15190071
68. Beasley DW, Barrett AD, Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein. J Virol. 2002;76(24):13097–100. 12438639
69. Wu KP, Wu CW, Tsao YP, Kuo TW, Lou YC, Lin CW, et al. Structural basis of a flavivirus recognized by its neutralizing antibody: solution structure of the domain III of the Japanese encephalitis virus envelope protein. J Biol Chem. 2003;278(46):46007–13. 12952958
70. Hung JJ, Hsieh MT, Young MJ, Kao CL, King CC, Chang W, An external loop region of domain III of dengue virus type 2 envelope protein is involved in serotype-specific binding to mosquito but not mammalian cells. J Virol. 2004;78(1):378–88. 14671119
71. Jaiswal S, Khanna N, Swaminathan S, High-level expression and one-step purification of recombinant dengue virus type 2 envelope domain III protein in Escherichia coli. Protein Expr Purif. 2004;33(1):80–91. 14680965
72. Sanchez-San Martin C, Nanda S, Zheng Y, Fields W, Kielian M, Cross-inhibition of chikungunya virus fusion and infection by alphavirus E1 domain III proteins. J Virol. 2013;87(13):7680–7. doi: 10.1128/JVI.00814-1323637415
73. Hepojoki J, Strandin T, Vaheri A, Lankinen H, Interactions and oligomerization of hantavirus glycoproteins. J Virol. 2010;84(1):227–42. doi: 10.1128/JVI.00481-0919828613
74. Badani H, Garry RF, Wimley WC, Peptide entry inhibitors of enveloped viruses: the importance of interfacial hydrophobicity. Biochim Biophys Acta. 2014;1838(9):2180–97. doi: 10.1016/j.bbamem.2014.04.01524780375
75. Wimley WC, White SH, Experimentally determined hydrophobicity scale for proteins at membrane interfaces. Nat Struct Biol. 1996;3(10):842–8. 8836100
76. White SH, Wimley WC, Hydrophobic interactions of peptides with membrane interfaces. Biochim Biophys Acta. 1998;1376(3):339–52. 9804985
77. Snider C, Jayasinghe S, Hristova K, White SH, MPEx: a tool for exploring membrane proteins. Prot Sci. 2009;18(12):2624–8.
78. Lee KK, Pessi A, Gui L, Santoprete A, Talekar A, Moscona A, et al. Capturing a fusion intermediate of influenza hemagglutinin with a cholesterol-conjugated peptide, a new antiviral strategy for influenza virus. J Biol Chem. 2011;286(49):42141–9. doi: 10.1074/jbc.M111.25424321994935
79. Ingallinella P, Bianchi E, Ladwa NA, Wang YJ, Hrin R, Veneziano M, et al. Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency. Proc Natl Acad Sci U S A. 2009;106(14):5801–6. doi: 10.1073/pnas.090100710619297617
80. Vigant F, Santos NC, Lee B, Broad-spectrum antivirals against viral fusion. Nat Rev Microbiol. 2015;13(7):426–37. doi: 10.1038/nrmicro347526075364